Bowel cancer — which includes cancer of the colon and rectum — is the fourth most common cancer in the UK and the second biggest cancer killer, claiming over 16,000 lives each year. With survival rates as high as 90% when caught at the earliest stage, and as low as 10% when diagnosed at Stage IV, few health questions carry more weight than this one: will a blood test show colon cancer? The honest answer is nuanced — and it is changing rapidly. Standard blood tests cannot diagnose colon cancer directly, but they can reveal important warning signals. Meanwhile, a new generation of blood-based technologies is beginning to transform what early detection looks like for UK patients.
Understanding exactly what different blood tests can and cannot tell you — and what to do if you have concerns — is the most important first step you can take.
What Routine Blood Tests Can and Cannot Show
A standard blood test panel cannot diagnose colon cancer. There is no single routine blood marker that confirms its presence reliably enough to replace colonoscopy or imaging. This matters in both directions: a normal blood result does not rule out colon cancer, and an abnormal result does not confirm it. What routine blood tests can do is flag physiological changes that the body produces in response to cancer — changes that, alongside symptoms and clinical assessment, can and should prompt further investigation.
According to Cancer Research UK, blood tests requested in the initial assessment of suspected bowel cancer typically serve to check general health and identify organ involvement, rather than to diagnose the cancer itself. Specific findings that may raise clinical concern include:
Anaemia
Bowel cancer — particularly right-sided colon cancer — frequently causes slow, occult (hidden) blood loss from the bowel wall over time. This ongoing blood loss depletes iron stores, leading to iron deficiency anaemia. A low haemoglobin or low mean corpuscular volume (MCV) on a full blood count, combined with a low ferritin on a separate iron study, is a recognised and important clinical pointer. Notably, research from Oxford University’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences has identified subtle but consistent changes in full blood count parameters — including red cell distribution width and platelet counts — in people with early-stage bowel cancer, appearing up to three years before diagnosis. A decision-support tool to help GPs identify these patterns earlier is currently in development.
Elevated Inflammatory Markers
A raised CRP (C-reactive protein) or ESR (erythrocyte sedimentation rate) indicates significant systemic inflammation and, while non-specific, can be a meaningful prompt for further investigation when found alongside relevant symptoms.
Liver Function Abnormalities
If colon cancer has spread to the liver, liver function tests may reveal elevated enzymes such as ALT or ALP. These findings are not specific to cancer but warrant further assessment, particularly in the context of other suspicious symptoms.
Elevated CEA (carcinoembryonic antigen)
CEA is a tumour marker that can be raised in colorectal cancer. However, it lacks the sensitivity and specificity needed for screening or diagnosis — it can be normal in early cancer and elevated in many benign conditions including smoking, liver disease, and inflammatory bowel disease. It is most useful for monitoring known colorectal cancer during and after treatment, rather than as an initial diagnostic tool.
Taken together, these findings can build a clinical picture that supports urgent referral. But they are starting points, not conclusions — and a GP who interprets them alongside your symptoms and risk factors is far better placed than any individual test result to determine what needs to happen next.
The NHS Bowel Cancer Screening Programme: What It Involves
For most people in England, the primary blood-based screening tool for bowel cancer is actually not a blood test at all — it is the faecal immunochemical test (FIT), a home testing kit that checks for tiny traces of blood in a stool sample. The NHS sends FIT kits to everyone aged 50 to 74 every two years as part of the national bowel cancer screening programme. Research suggests that detecting bowel cancer at the earliest stage makes you up to nine times more likely to be successfully treated — which is precisely why participation matters so much.
According to NHS screening guidance, around 97 to 98 people in every 100 who complete the FIT test will not need any further tests. For the 2 to 3 in every 100 where blood is detected, the next step is typically a colonoscopy — a camera test that looks at the inside of the large bowel and allows suspicious polyps or growths to be sampled or removed. A positive FIT result does not mean cancer is present; blood in stool has many benign causes. But it does mean further investigation is needed, and promptly.
If you are between the ages covered by the screening programme and have not received your kit, or if you are outside the screening age range and have relevant symptoms, do not wait for an invitation. Contact a GP to discuss your concerns directly.
Lynch Syndrome: When a Blood Test Is the Starting Point
There is one important context in which a blood test plays a central and direct role in bowel cancer risk assessment — Lynch syndrome. This inherited genetic condition, caused by mutations in DNA mismatch repair genes, significantly increases the lifetime risk of bowel cancer (and several other cancers), often at a younger age than the general population. NHS England estimates that around 1 in 400 people in England carry Lynch syndrome, though only around 5% are currently aware of it.
Since 2024, the NHS has been able to identify Lynch syndrome through a genomic blood test, which is processed through regional laboratory hubs. Almost all people newly diagnosed with bowel cancer in England now receive an initial Lynch syndrome test — a figure that has risen from 47% in 2019 to 94% by 2023. People confirmed as having Lynch syndrome are then offered regular colonoscopy surveillance, and their family members can be referred for genetic testing. If you have a strong family history of bowel cancer — particularly at a young age, or across multiple generations — discussing genetic testing with your GP is a meaningful and potentially life-saving conversation.
The Galleri Test: What the NHS Trial Results Really Mean
The most significant recent development in blood-based cancer detection is the Galleri multi-cancer early detection (MCED) test — a blood test that analyses methylation patterns in cell-free DNA shed by tumour cells into the bloodstream, with the aim of detecting signals from more than 50 cancer types, including colorectal cancer, before symptoms appear.
In February 2026, the results of the landmark NHS-Galleri trial — a randomised controlled trial involving 142,000 participants aged 50 to 77 across England, run by Cancer Research UK and King’s College London in partnership with NHS England and GRAIL — were published. The results present a nuanced picture. The trial did not achieve its prespecified primary endpoint of a statistically significant reduction in combined Stage III and IV cancer diagnoses. However, several secondary findings are clinically meaningful: adding Galleri to standard screening produced a substantial reduction in Stage IV diagnoses across a prespecified group of 12 deadly cancers — including colorectal cancer — with a greater than 20% reduction observed in the second and third screening rounds. The trial also demonstrated a four-fold improvement in overall cancer detection rate compared with standard screening alone for colorectal, breast, cervical, and high-risk lung cancers.
It is important to be clear about what this means for UK patients today. The Galleri test is not currently available outside of a clinical trial setting on the NHS, and Cancer Research UK states explicitly that it is not available in the UK outside of a clinical trial. The NHS-Galleri data will now inform a decision about whether a national screening programme is warranted. The science is genuinely promising — but the technology has not yet completed the regulatory and evidence journey needed for routine clinical use. Caution is warranted about private providers offering multi-cancer early detection tests outside of a clinical governance framework, and any such offer should be discussed with a GP before proceeding.
Symptoms That Should Prompt Urgent Assessment
Bowel cancer is described by the Peninsula Cancer Alliance NHS as having a lack of red flag symptoms in many cases — which is one reason why screening and early assessment are so important. However, the following symptoms should always prompt a GP consultation rather than a wait-and-see approach:
- A persistent change in bowel habit — going more or less frequently, or alternating between diarrhoea and constipation — lasting three weeks or more
- Blood in your stool, or bleeding from the back passage, even once
- Unexplained weight loss
- Persistent abdominal pain, cramping, or discomfort
- A feeling that your bowel has not emptied properly after going to the toilet
- Unexplained fatigue or breathlessness — which may indicate anaemia from occult bowel bleeding
- A lump in the abdomen or back passage noticed by you or a clinician
It is important to know that most people with these symptoms will not have bowel cancer — they are shared by many common and benign conditions including irritable bowel syndrome, haemorrhoids, and inflammatory bowel disease. But all of them deserve investigation rather than assumption, particularly if they are new, persistent, or accompanied by other concerning features.
At The Private GP in Birmingham, a face-to-face GP consultation gives you prompt access to a GMC-registered doctor who will take your symptoms seriously, arrange appropriate blood testing, and refer urgently for further investigation where indicated — without the wait of an NHS appointment. NICE recommends that anyone referred on a suspected cancer pathway receives a diagnosis or ruling out within 28 days of referral. If you are concerned, acting quickly is always the right decision.
What a Private Blood Test Can Offer Right Now
While no blood test can independently diagnose colon cancer, a comprehensive private blood test in Birmingham that includes a full blood count, iron studies, inflammatory markers, liver function tests, and CEA can provide a clinically meaningful starting point — particularly if you have symptoms, a family history of bowel cancer, or simply want to understand your baseline health more thoroughly. Same-day results with GP interpretation ensure that any findings are acted upon promptly and in the right clinical context.
Where further investigation is needed — whether imaging, specialist referral, or an MRI or CT scan — we can arrange this quickly and efficiently, ensuring you are never left waiting for the next step. Early detection saves lives. The most important thing you can do if you have concerns is to seek assessment now rather than later.
Frequently Asked Questions
- Can a full blood count detect bowel cancer?
A full blood count (FBC) cannot diagnose bowel cancer directly, but research from Oxford University has identified subtle, consistent changes in FBC parameters — including red cell distribution width and platelet count — in people with early bowel cancer, appearing up to three years before formal diagnosis. In clinical practice, iron deficiency anaemia flagged on an FBC is one of the most important prompts for bowel cancer investigation, particularly in older adults. A normal FBC does not rule out bowel cancer, especially at an early stage.
- Is the NHS bowel cancer screening test a blood test?
No. The primary NHS bowel cancer screening tool is the faecal immunochemical test (FIT) — a home kit that checks a small stool sample for traces of blood invisible to the naked eye. It is sent automatically to everyone aged 50 to 74 in England every two years. Blood tests are used as part of the subsequent assessment process when symptoms or a positive FIT result prompt further investigation, not as the initial screening tool itself.
- What is the Galleri test and can I have it in the UK?
The Galleri test is a multi-cancer early detection (MCED) blood test that analyses cell-free DNA for cancer-associated methylation signals across more than 50 cancer types, including colorectal cancer. It was evaluated in the NHS-Galleri trial — involving 142,000 participants — whose topline results were published in February 2026. The trial showed promising secondary findings, including a reduction in late-stage diagnoses and improved early detection rates, but did not achieve its primary endpoint. The test is not currently available outside of a clinical trial in the UK. A private GP consultation can help you understand your options and what investigations are appropriate for your circumstances.
- What blood tests are done when bowel cancer is suspected?
According to Cancer Research UK and NHS clinical guidance, blood tests requested when bowel cancer is suspected typically include a full blood count (to check for anaemia and platelet changes), iron studies, liver function tests, kidney function, and sometimes a CEA tumour marker. These tests assess general health, identify organ involvement, and support the case for urgent specialist referral. They are used alongside — not instead of — the FIT test and colonoscopy in the diagnostic pathway. At The Private GP, a private blood test can cover all of these markers with same-day results.
- Should I see a GP if I have bowel cancer symptoms?
Yes — and promptly. Bowel cancer is significantly more treatable when caught early: survival at Stage I is around 90%, compared with around 10% at Stage IV. Symptoms including a persistent change in bowel habit, rectal bleeding, unexplained weight loss, or fatigue should never be left to resolve on their own. At The Private GP in Birmingham, same-day appointments are available with no lengthy waiting times. If further investigation is needed, we can facilitate rapid access to imaging and specialist referral.